Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00966693 · ClinicalTrials.gov registry record · Phase 1
Lenalidomide, Thalidomide and Dexamethasone in Treating Participants With Relapsed or Refractory Multiple Myeloma
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 77
- Enrollment target
NCT00966693: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT00966693 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 77 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00966693, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 77 participants
- Enrollment target
Study Summary
This phase I/II trial studies the best dose and side effects of lenalidomide and thalidomide, and how well they work with dexamethasone in treating participants with multiple myeloma that has come back or does not respond to treatment. Drugs used in chemotherapy, such as lenalidomide, thalidomide and dexamethasone, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Interventions
- DRUG Dexamethasone
- DRUG Lenalidomide
- DRUG Thalidomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 77 participants |
| Start Date | 2009-08-25 |
| Est. Completion | 2018-07-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00966693
The ClinicalTrials.gov registry entry for NCT00966693 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 77 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Dexamethasone is the first listed.
NCT00966693 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00966693 about?
NCT00966693 is a clinical study titled "Lenalidomide, Thalidomide and Dexamethasone in Treating Participants With Relapsed or Refractory Multiple Myeloma". This phase I/II trial studies the best dose and side effects of lenalidomide and thalidomide, and how well they work with dexamethasone in treating participants with multiple myeloma that has come back or does not respond to treatment. Drugs used in chemotherapy, such as lenalidomide, thalidomide an...
What is the current status of trial NCT00966693?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 77 participants. The study started on 2009-08-25. Estimated completion is 2018-07-20.
What interventions are being tested in trial NCT00966693?
The interventions under investigation include: Dexamethasone (DRUG), Lenalidomide (DRUG), Thalidomide (DRUG).
Who is sponsoring clinical trial NCT00966693?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.